Bayesian parameter estimates of nelfinavir and its active metabolite, hydroxy-tert-butylamide, in infants perinatally infected with human immunodeficiency virus type 1

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 2, 2005, Pages 525-535

  Payen, Salomé ^a   Faye, Albert ^b   Compagnucci, Alexandra ^c   Giaquinto, Carlo ^d   Gibbs, Diana ^e   Gomeni, Roberto ^a,f   Bressolle, Françoise ^a   Jacqz Aigrain, Evelyne ^b  

^a UNIV MONTPELLIER   (France)

^b HÔPITAL ROBERT DEBRÉ   (France)

^c INSERM   (France)

^d UNIVERSITY OF PADOVA   (Italy)

^e MRC CLINICAL TRIALS UNIT   (United Kingdom)

^f GSK   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; HYDROXY TERT BUTYLAMIDE; NELFINAVIR; STAVUDINE; UNCLASSIFIED DRUG;

ARTICLE; BAYES THEOREM; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; ELECTROSPRAY MASS SPECTROMETRY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; LIQUID CHROMATOGRAPHY; MALE; METABOLIC RATE; PERINATAL INFECTION; PRIORITY JOURNAL; VERTICAL TRANSMISSION;

AGING; BAYES THEOREM; BODY WEIGHT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIDANOSINE; DRUG INTERACTIONS; HALF-LIFE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INFANT; INFANT, NEWBORN; MODELS, BIOLOGICAL; NELFINAVIR; REVERSE TRANSCRIPTASE INHIBITORS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; STAVUDINE;

EID: 12944260577     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.2.525-535.2005     Document Type: Article

References (28)

1. Bardsley-Elliot, A., and G. L. Plosker. 2000. Nelfinavir, an update of its use in HIV infection. Drugs 59:581-620.
2. Beal, S. L., and L. B. Sheiner. 1994. NONMEM user's guide. University of California at San Francisco, San Francisco, Calif.
3. Bergshoeff, A. S., P. L. Fraaij, A. M. van Rossum, T. F. Wolfs, S. P. Geelen, R. de Groot, and D. M. Burger. 2003. Pharmacokinetics of nelfinavir in children: influencing factors and dose implications. Antivir. Ther. 8:215-222.
4. Capparelli, E. V., J. L. Sullivan, L. Mofenson, E. Smith, B. Graham, P. Britto, M. I. Becker, D. Holland, J. D. Connor, and K. Luzuriaga. 2001. Pharmacokinetics of nelfinavir in human immunodeficiency virus-infected infants. Pediatr. Infect. Dis. J. 20:746-751.
5. Centers for Disease Control and Prevention. 1998. Guidelines for the use of antiretroviral agents in pediatric HIV infection. Morb. Mortal. Wkly. Rep. 47:1-45.
6. Farenc, C., J. R. Fabreguette, and F. Bressolle. 2000. Pk-fit: a pharmacokinetic/pharmacodynamic and statistical data analysis software. Comput. Biomed. Res. 33:315-330.
7. Floren, L. C., A. Wiznia, S. Hayashi, A. Jayewardene, K. Stanley, G. Johnson, S. Nachman, P. Krogstad, and F. T. Aweeka. 2003. Nelfinavir pharmacokinetics in stable human immunodeficiency virus-positive children: Pediatric AIDS Clinical Trials Group Protocol 377. Pediatrics 112: 220-227.
8. Funk, M. B., R. Linde, U. Wintergerst, G. Notheis, F. Hoffmann, T. Schuster, B. Kornhuber, P. Ahrens, and W. Kreuz. 1999. Preliminary experiences with triple therapy including nelfinavir and two reverse transcriptase inhibitors in previously untreated HIV-infected children. AIDS 13:1653-1658.
9. Gatti, G., G. Castelli-Gattinara, M. Cruciani, S. Bernardi, C. R. De Pascalis, E. Pontali, L. Papa, F. Miletich, and D. Bassetti. 2003. Pharmacokinetics and pharmacodynamics of nelfinavir administered twice or thrice daily to human immunodeficiency virus type-1-infected children. Clin. Infect. Dis. 36:1476-1482.
10. Gulik, R. M., J. H. Mellors, D. Havlir, J. J. Eron, C. Gonzalez, and D. McMahon. 1997. Treatment with indinavir, zidovudine and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N. Engl. J. Med. 337:734-739.
11. Hammer, S. M., K. E. Squires, M. D. Hughes, J. M. Grimes, L. M. Demeter, J. S. Currier, J. J. Eron, Jr., J. E. Feinberg, H. H. Balfour, Jr., L. R. Deyton, J. A. Chodakewitz, M. A. Fischl, et al. 1997. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N. Engl. J. Med. 337:725-733.
12. Krogstad, P., A. Wiznia, K. Luzuriaga, W. Dankner, K. Nielsen, M. Gersten, B. Kerr, A. Hendricks, B. Boczany, M. Rosenberg, D. Jung, S. A. Spector, and Y. Bryson. 1999. Treatment of human immunodeficiency virus 1-infected infants and children with the protease inhibitor nelfinavir mesylate. Clin. Infect. Dis. 28:1109-1118.
13. Litalien, C., A. Faye, A. Compagnucci, C. Giaquinto, L. Harper, D. M. Gibb, and E. Jacqz-Aigrain. 2003. Pharmacokinetics of nelfinavir and its active metabolite, hydroxy-tert-butylamide, in infants perinatally infected with human immunodeficiency virus type 1. Pediatr. Infect. Dis. J. 22:48-55.
14. Malaty, L. I., and J. J. Kuper. 1999. Drug interactions of HIV protease inhibitors. Drug Safety 20:147-169.
15. Montaner, J. S., P. Reiss, D. Cooper, S. Vella, M. Harris, B. Conway, M. A. Wainberg, D. Smith, P. Robinson, D. Hall, M. Myers, and J. M. Lange. 1998, A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia study. JAMA 279:930-937.
16. Pai, V. B., and M. C. Nahata. 1999. Nelfinavir mesylate: a protease inhibitor. Ann. Pharmacother. 33:325-339.
17. Patick, A. K., H. Mo, M. Markowitz, K. Appelt, B. Wu, L. Musick, V. Kalish, S. Kaldor, S. Reich, D. Ho, and S. Webber. 1996. Design, synthesis, and evaluation of nonpeptidic inhibitors of human rhinovirus 3C protease. J. Med. Chem. 39:5072-5082.
18. Perry, C. M., and P. Benfield. 1997. Nelfinavir. Drugs 54:81-87.
19. Powderly, W. G., M. S. Saag, S. Chapman, G. Yu, B. Quart, and N. J. Clendeninn. 1999. Predictors of optimal virological response to potent antiretroviral therapy. AIDS 13:1873-1980.
20. Research Development Population Pharmacokinetics. 1998. Visual-NM user's manual, version 5.1. Research Development Population Pharmacokinetics, Montpellier, France.
21. Rongkavilit, C., R. P. van Heeswijk, S. Limpongsanurak, P. Thaithumyanon, C. Boonrod, E. A. Hassink, A. Srigritsanapol, T. Chuenyam, S. Ubolyam, R. M. Hoetelmans, K. Ruxrungtham, J. M., Lange, D. A. Cooper, and P. Phanuphak. 2002. Dose-escalating study of the safety and pharmacokinetics of nelfinavir in HIV-exposed neonates. J. Acquir. Immune Defic. Syndr. 29: 455-463.
22. Schuster, T., R. Linde, U. Wintergerst, M. B. Funk, M. Kurowski, W. Kreuz, and D. Hofmann. 2000. Nelfinavir pharmacokinetics in HIV-infected children: a comparison of twice daily and three time daily dosing. AIDS 14: 1466-1468.
23. Shearer, W. T., T. C. Quinn, P. LaRussa, J. F. Lew, L. Mofenson, S. Almy, K. Rich, E. Handelsman, C. Diaz, M. Pagano, V. Smeriglio, L. A. Kalish, et al. 1997. Viral load and disease progression in infants infected with human immunodeficiency virus type 1. N. Engl. J. Med. 336:1337-1342.
24. Sheiner, L. B., and S. L. Beal. 1981. Some suggestions for measuring predictive performance. J. Pharmacokinet. Biopharm. 9:503-512.
25. Sheiner, L. B., and S. L. Beal. 1981. Evaluation of methods for estimating population pharmacokinetic parameters. II. Biexponential model and experimental pharmacokinetic data. J. Pharmacokinet. Biopharm. 9:635-651.
26. Starr, S. E., C. V. Fletcher, S. A. Spector, F. H. Yong, T. Fenton, R. C. Brundage, D. Manion, N. M. Ruiz, M. Gersten, M. Becker, J. McNamara, and L. M. Mofenson for The Pediatric AIDS Clinical Trials Group 382 Team. 1999. Combination therapy with efavirenz, nelfinavir, and nudeoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. N. Engl. J. Med. 341:1874-1881.
27. van Heeswijk, R. P., H. J. Scherpbier, L. A. de Koning, H. S. Heymans, J. M. Lange, J. H. Beijnen, and R. M. Hoetelmans. 2002. The pharmacokinetics of nelfinavir in HIV-1-infected children. Ther. Drug Monit. 24:487-491.
28. Zhang, K. E., E. Wu, A. K. Patick, B. Kerr, M. Zorbas, A. Lankford, T. Kobayashi, Y. Maeda, B. Shetty, and S. Webber. 2001. Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: structural identification, levels in plasma, and antiviral activities. Antimicrob. Agents Chemother. 45:1086-1093. (Erratum, 45:2405.)